Bio News
Dong-A ST reported second-quarter sales of 207.8 billion won, up 17.2% from a year earlier, while completing the global Phase 2a trial of its MASH treatment DA-1241. The obesity treatment DA-1726 is undergoing Part 3 of a global Phase 1 trial, while two other candidates, including the tau inhibitor DA-7503, are in domestic Phase 1 trials. Xcopri is scheduled to launch in the second half of the year.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
